Neurogene
NGNE
60 hedge funds and large institutions have $617M invested in Neurogene in 2024 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 7 closing their positions.
357% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 7
233% more capital invested
Capital invested by funds: $186M → $617M (+$432M)
71% more funds holding
Funds holding: 35 → 60 (+25)
19.71% more ownership
Funds ownership: 74.68% → 94.39% (+20%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$27.7M |
| 2 |
RI
RTW Investments
New York
|
+$25.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.3M |
| 4 |
CC
Commodore Capital
New York
|
+$6.68M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.93M |
| 2 |
Morgan Stanley
New York
|
-$5.46M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.94M |
| 4 |
Walleye Capital
New York
|
-$2.93M |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.46M |
NGNE Hedge Fund Activity: Q1 2024 in Review
60 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q1 2024, worth a combined $617M — up 233% from $186M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new NGNE positions and 7 closed out — a net gain of 25 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $27.7M. The largest seller was Cormorant Asset Management, cutting an estimated $6.93M.
- 60 institutional investors held Neurogene (NGNE) as of Q1 2024, up from 35 in Q4 2023.
- Funds reported $617M of Neurogene stock for Q1 2024, up 233% quarter-over-quarter.
- 32 funds opened new Neurogene positions in Q1 2024 and 7 closed out, a net change of +25 holders.
- The largest Neurogene buyer in Q1 2024 was BlackRock, an estimated $27.7M added.
- The largest Neurogene seller in Q1 2024 was Cormorant Asset Management, an estimated $6.93M sold.
Based on aggregated 13F filings for Q1 2024.